|
|||||
|
|
Randomized phase 2 study of bone‐targeted therapy containing strontium‐89 in advanced castrate‐sensitive prostate cancer |
|
| Authors: | Mehmet Asim Bilen MD Marcella M. Johnson MS Paul Mathew MD Lance C. Pagliaro MD John C. Araujo MD PhD Ana Aparicio MD Paul G. Corn MD PhD Nizar M. Tannir MD Franklin C. Wong MD Michael J. Fisch MD Christopher J. Logothetis MD Shi‐Ming Tu MD |
| Affiliation: | 1. Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas;2. Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, Texas;3. Department of Hematology/Oncology, Tufts Medical Center, Boston, MA;4. Department of Nuclear Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas;5. Department of General Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas |
| Abstract: | |
| Keywords: | bone metastasis phase 2 prostate cancer radiopharmaceutical strontium‐89 |